 The study conducted in Russia showed that elevated levels of non-high-density lipoprotein cholesterol, non-HDLC, are strongly associated with an increased risk of cardiovascular events. This suggests that non-HDLC should be included as a component of cardiovascular risk assessment tools such as the SCOR2 and SCOROP models. Continuous monitoring of endpoints is necessary to establish stable associations between non-HDLC and cardiovascular outcomes. This article was authored by S.A. Shalnova, V.A. Metalskaya, V.A. Kutsenko, and others.